CYTK Latest Press Releases

-- October 21, 2026 --

Cytokinetics to Announce Third Quarter Results on November 4, 2026 Globe Newswire 4:00 PM

-- October 19, 2026 --

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

Cytokinetics Announces Health Canada Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Globe Newswire 7:30 AM

-- October 12, 2026 --

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026 Globe Newswire 4:00 PM

-- October 2, 2026 --

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026 Globe Newswire 7:30 AM

-- September 30, 2026 --

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy Globe Newswire 7:30 AM

-- September 17, 2026 --

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- September 14, 2026 --

Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program Globe Newswire 7:30 AM

-- September 2, 2026 --

Cytokinetics to Participate in September Investor Conferences Globe Newswire 4:00 PM

-- August 29, 2026 --

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 Globe Newswire 10:30 AM

-- August 28, 2026 --

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine Globe Newswire 5:45 AM

-- August 20, 2026 --

Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 Globe Newswire 7:30 AM

-- August 18, 2026 --

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- August 6, 2026 --

Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:00 PM

-- July 30, 2026 --

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO? (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales Globe Newswire 6:20 AM

-- July 23, 2026 --

Cytokinetics to Announce Second Quarter Results on August 6, 2026 Globe Newswire 4:00 PM

-- July 17, 2026 --

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- July 7, 2026 --

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 Globe Newswire 7:30 AM

-- June 17, 2026 --

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- June 8, 2026 --

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program Globe Newswire 7:30 AM

-- June 1, 2026 --

Cytokinetics Launches MYQORZO (aficamten) in European Union, with First Commercial Availability in Germany Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes